VIP and Arthritis: Furthermore, administration of the VIP receptor antagonist VIP6–28 into the knee joint of rats with monoiodacetate-induced arthritis was able to reduce this pain behavior, thereby showing for the first time that peripheral application of VIP causes increased knee joint allodynia and secondary hyperalgesia.